The total number of shares in Biovitrum AB (publ) as per April 30, 2010 amounts
to 212,414,439 shares, whereof 211,898,854 common shares and 515,585 class C
shares[1], corresponding to in total 211,950,412.50 votes. The increase in the
number of shares and votes results from a conversion of previously issued
convertibles into a total of 2,373,300 common shares to the vendors of Cambridge
Biotechnology Limited.
For further information, please contact:
Göran Arvidson, CFO Biovitrum
Phone: +46 70 633 30 42
Erik Kinnman, EVP Investor Relations Biovitrum
Phone: +46 73 422 15 40
erik.kinnman@biovitrum.com <mailto:erik.kinnman@biovitrum.com>
About Swedish Orphan Biovitrum
On January 14, 2010, Biovitrum AB (publ) completed the acquisition of Swedish
Orphan International Holding AB and created Swedish Orphan Biovitrum - a leading
company focused on treatment of rare diseases.
Swedish Orphan Biovitrum is a Swedish based specialty pharmaceutical company
with an international market presence. The company is focused on providing and
developing orphan and niche specialist pharmaceuticals to patients with high
medical needs. The portfolio consists of about 60 marketed products and an
emerging late stage clinical development pipe-line within rare diseases. Swedish
Orphan Biovitrum has pro-forma revenues 2009e of about 2 BSEK and approximately
500 employees. The head office is located in Sweden and the share (STO: BVT) is
listed on NASDAQ OMX Stockholm. For more information please visit
www.biovitrum.com <http://www.biovitrum.com/>.
The above information has been made public in accordance with the Securities
Market Act and/or the Financial Instruments Trading Act. The information was
published at 11:45 a.m CET on April 30, 2010.
--------------------------------------------------------------------------------
[1] All class C shares are held by Biovitrum.
[HUG#1410497]
